Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endostar + chemotherapy (Simcere Pharmaceutical Group)
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
Endostar (recombinant human endostatin) is a biologic anti-angiogenic agent developed by Simcere Pharmaceutical. It is a 20 kDa fragment of type XVIII collagen that inhibits tumor growth by targeting vascular endothelial cells, inhibiting their migration and proliferation, and promoting vascular normalization. In the clinical trial conducted by Zhejiang Cancer Hospital, Endostar is combined with physician's choice chemotherapy (typically taxane-based) for the treatment of HER-2 negative advanced or metastatic breast cancer. This combination therapy aims to improve the delivery and efficacy of cytotoxic agents by stabilizing the tumor microenvironment and enhancing the antitumor effects of chemotherapy.
- Brand names
- Endostar
- Other names
- recombinant human endostatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on Endostar + chemotherapy (Simcere Pharmaceutical Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endostar + chemotherapy (Simcere Pharmaceutical Group).